Value-based insurance design in oncology
Lancet Oncol
.
2011 Apr;12(4):321-3.
doi: 10.1016/S1470-2045(11)70043-2.
Authors
Jonas A de Souza
1
,
Blase N Polite
,
Willard G Manning
,
A Mark Fendrick
,
Mark J Ratain
Affiliation
1
Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA.
PMID:
21463832
DOI:
10.1016/S1470-2045(11)70043-2
No abstract available
Publication types
Research Support, Non-U.S. Gov't
MeSH terms
Antineoplastic Agents / economics*
Cost Sharing / economics*
Cost-Benefit Analysis
Humans
Insurance, Health, Reimbursement / economics*
Substances
Antineoplastic Agents